Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...

Wells Fargo analyst Derek Archila maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $17.00. The ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

- Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET WILMINGTON, Del., March 17, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive ...

Shares of Incyte Corp. slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.64% to 5,675.12 and the Dow Jones ...

(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other ...

BANGALORE, India, March 17, 2025 /PRNewswire/ -- Micro Bioreactor System Market is Segmented by Type (48 Parallel, 24 Parallel), by Application (Pharmaceutical, Sewage Treatment, Biochemical ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...